Lexicon Pharmaceuticals Inc (LXRX)
0.8634
+0.09
(+11.88%)
USD |
NASDAQ |
Nov 22, 16:00
0.8755
+0.01
(+1.40%)
After-Hours: 20:00
Lexicon Pharmaceuticals Enterprise Value: 153.64M for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 153.64M |
| November 21, 2024 | 120.49M |
| November 20, 2024 | 133.39M |
| November 19, 2024 | 159.96M |
| November 18, 2024 | 168.68M |
| November 15, 2024 | 194.05M |
| November 14, 2024 | 224.71M |
| November 13, 2024 | 235.55M |
| November 12, 2024 | 271.70M |
| November 11, 2024 | 300.62M |
| November 08, 2024 | 300.62M |
| November 07, 2024 | 311.47M |
| November 06, 2024 | 278.93M |
| November 05, 2024 | 271.70M |
| November 04, 2024 | 277.12M |
| November 01, 2024 | 282.55M |
| October 31, 2024 | 546.44M |
| October 30, 2024 | 546.44M |
| October 29, 2024 | 575.36M |
| October 28, 2024 | 513.90M |
| October 25, 2024 | 492.21M |
| October 24, 2024 | 506.67M |
| October 23, 2024 | 513.90M |
| October 22, 2024 | 542.82M |
| October 21, 2024 | 546.44M |
| Date | Value |
|---|---|
| October 18, 2024 | 593.43M |
| October 17, 2024 | 568.13M |
| October 16, 2024 | 531.98M |
| October 15, 2024 | 488.60M |
| October 14, 2024 | 488.60M |
| October 11, 2024 | 470.52M |
| October 10, 2024 | 452.45M |
| October 09, 2024 | 430.76M |
| October 08, 2024 | 448.83M |
| October 07, 2024 | 448.83M |
| October 04, 2024 | 452.45M |
| October 03, 2024 | 423.53M |
| October 02, 2024 | 423.53M |
| October 01, 2024 | 412.68M |
| September 30, 2024 | 409.07M |
| September 27, 2024 | 367.92M |
| September 26, 2024 | 346.23M |
| September 25, 2024 | 335.39M |
| September 24, 2024 | 357.08M |
| September 23, 2024 | 360.69M |
| September 20, 2024 | 389.61M |
| September 19, 2024 | 400.46M |
| September 18, 2024 | 382.38M |
| September 17, 2024 | 375.15M |
| September 16, 2024 | 378.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
32.22M
Minimum
Nov 02 2020
1.146B
Maximum
Feb 02 2021
375.49M
Average
353.46M
Median
Aug 07 2024
Enterprise Value Benchmarks
| Viatris Inc | 29.66B |
| Halozyme Therapeutics Inc | 7.072B |
| Perspective Therapeutics Inc | -31.63M |
| Quanterix Corp | 154.10M |
| Autonomix Medical Inc | 3.166M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -64.81M |
| Revenue (Quarterly) | 1.75M |
| Total Expenses (Quarterly) | 65.44M |
| EPS Diluted (Quarterly) | -0.18 |
| Gross Profit Margin (Quarterly) | 95.94% |
| Profit Margin (Quarterly) | -3.70K% |
| Earnings Yield | -86.87% |
| Normalized Earnings Yield | -86.87 |